Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PAVEL ALEKSANDER LEVIN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1528352614
CMS profile
1306534
Location
PEARLAND, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$4,085.73

173 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,901.60 170
Education $184.13 3

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Biotech, Inc. $302.39 9
Novartis Pharmaceuticals Corporation $291.06 13
AstraZeneca Pharmaceuticals LP $283.65 13
PFIZER INC. $256.48 16
E.R. Squibb & Sons, L.L.C. $245.30 14
Merck Sharp & Dohme LLC $219.11 8
GENZYME CORPORATION $210.87 7
Astellas Pharma US Inc $184.55 5
Celgene Corporation $183.43 6
Lilly USA, LLC $119.26 4
TerSera Therapeutics LLC $110.72 4
Eisai Inc. $107.05 5
Takeda Pharmaceuticals U.S.A., Inc. $103.67 4
AVEO Pharmaceuticals, Inc. $91.10 3
Karyopharm Therapeutics Inc. $88.45 4
Puma Biotechnology, Inc. $82.20 5
Incyte Corporation $79.60 4
Alexion Pharmaceuticals, Inc. $79.42 3
Seagen Inc. $66.89 3
CTI BioPharma Corp. $65.23 3
Genentech USA, Inc. $63.87 3
TAIHO ONCOLOGY, INC. $61.06 3
Pharming Healthcare, Inc. $58.46 3
BeiGene USA, Inc. $55.64 3
Gilead Sciences, Inc. $53.04 2
Daiichi Sankyo Inc. $52.56 2
PharmaEssentia USA Corporation $49.58 2
Amgen Inc. $40.42 2
Kyowa Kirin, Inc. $37.85 2
Rigel Pharmaceuticals, Inc. $36.25 1
Pharmacyclics LLC, An AbbVie Company $34.51 1
SOBI, INC $31.56 1
Pharmacosmos Therapeutics Inc. $31.36 1
Exelixis Inc. $30.46 2
Boston Scientific Corporation $27.72 1
ABBVIE INC. $27.13 1
GlaxoSmithKline, LLC. $26.17 1
ARRAY BIOPHARMA INC $25.39 1
Sirtex Medical Inc $25.29 1
Stemline Therapeutics Inc. $24.71 1
MorphoSys, US Inc. $24.24 1
Bayer Healthcare Pharmaceuticals Inc. $23.06 1
JAZZ PHARMACEUTICALS INC. $21.84 1
Helsinn Therapeutics (U.S.), Inc. $18.04 1
Kite Pharma, Inc. $17.91 1
Sumitomo Pharma America, Inc. $17.18 1

Page 2 of 4; records 51–100 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PAVEL ALEKSANDER LEVIN

NPI 1528352614 · CMS profile ID 1306534

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

PEARLAND, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1528352614?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PAVEL ALEKSANDER LEVIN, NPI 1528352614, CMS profile ID 1306534. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1528352614?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). PAVEL ALEKSANDER LEVIN, NPI 1528352614, CMS profile ID 1306534. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1528352614?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
PAVEL ALEKSANDER LEVIN, NPI 1528352614, CMS profile ID 1306534, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1528352614?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

173 matching records · $4,085.73 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 173 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 173.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
CTI BioPharma Corp. $25.9809/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039695033 CMS
Gilead Sciences, Inc. $18.5409/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025873241 CMS
Celgene Corporation $28.8309/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015507549 CMS
GENZYME CORPORATION $33.0809/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050323491 CMS
Janssen Biotech, Inc. $43.9109/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988489387 CMS
Novartis Pharmaceuticals Corporation $25.9109/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992021293 CMS
Incyte Corporation $18.4709/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044620987 CMS
Alexion Pharmaceuticals, Inc. $22.0609/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017090057 CMS
Novartis Pharmaceuticals Corporation $21.2409/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992021287 CMS
Novartis Pharmaceuticals Corporation $19.7109/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992021291 CMS
Karyopharm Therapeutics Inc. $26.0008/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056906659 CMS
Eisai Inc. $21.2408/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023326861 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.5008/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055454131 CMS
AstraZeneca Pharmaceuticals LP $16.3908/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011347001 CMS
Takeda Pharmaceuticals U.S.A., Inc. $34.6408/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055454125 CMS
TerSera Therapeutics LLC $24.8908/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052422097 CMS
AstraZeneca Pharmaceuticals LP $32.8308/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016154067 CMS
TAIHO ONCOLOGY, INC. $24.0708/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055230301 CMS
GENZYME CORPORATION $24.1208/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050323469 CMS
Sumitomo Pharma America, Inc. $17.1808/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030864849 CMS
Puma Biotechnology, Inc. $19.1208/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059060943 CMS
Helsinn Therapeutics (U.S.), Inc. $18.0408/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058019973 CMS
Merck Sharp & Dohme LLC $23.8108/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048422293 CMS
Pharmacosmos Therapeutics Inc. $31.3608/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046254721 CMS
Genentech USA, Inc. $24.8208/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040501567 CMS
Rigel Pharmaceuticals, Inc. $36.2508/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033416423 CMS
GENZYME CORPORATION $20.9308/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050323465 CMS
AstraZeneca Pharmaceuticals LP $22.2807/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015037573 CMS
Stemline Therapeutics Inc. $24.7107/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040035249 CMS
Astellas Pharma US Inc $98.0007/27/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034343687 CMS
Gilead Sciences, Inc. $34.5007/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025541363 CMS
Lilly USA, LLC $30.6607/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032097539 CMS
ARRAY BIOPHARMA INC $25.3907/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050487475 CMS
Celgene Corporation $28.1407/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015507505 CMS
Novartis Pharmaceuticals Corporation $15.8507/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992021279 CMS
AstraZeneca Pharmaceuticals LP $17.8207/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011745597 CMS
Merck Sharp & Dohme LLC $34.5607/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048422409 CMS
PFIZER INC. $18.4607/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050704357 CMS
Puma Biotechnology, Inc. $13.1907/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059063041 CMS
Astellas Pharma US Inc $30.7507/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034271363 CMS
Boston Scientific Corporation $27.7207/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022005165 CMS
Novartis Pharmaceuticals Corporation $21.9007/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992021275 CMS
E.R. Squibb & Sons, L.L.C. $16.1107/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015507497 CMS
Celgene Corporation $29.4507/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015507489 CMS
Genentech USA, Inc. $22.1606/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040501555 CMS
Eisai Inc. $21.5006/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023326863 CMS
Pharming Healthcare, Inc. $20.0006/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029339512 CMS
Genentech USA, Inc. $16.8906/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040501571 CMS
Incyte Corporation $16.6206/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044620249 CMS
Pharmacyclics LLC, An AbbVie Company $34.5106/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998289649 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,035.22 24
PY2020 $175.84 7
PY2021 $211.78 6
PY2022 $4,692.03 65
PY2023 $4,085.73 173
PY2024 $10,391.11 199
PY2025 $8,331.36 176

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $169,413.92 24
PY2024 Principal investigator $179,892.31 6
PY2023 Principal investigator $29,698.33 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

24 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Texas Oncology Gulf Coast
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715585
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Texas Oncology Gulf Coast
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715587
Principal investigator 1 PFIZER INC. $3,187.76 12/08/2025 Non-covered Recipient Entity
Texas Oncology Gulf Coast
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715589
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Texas Oncology Gulf Coast
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715669
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Texas Oncology Gulf Coast
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715671
Principal investigator 1 PFIZER INC. $26.00 12/08/2025 Non-covered Recipient Entity
Texas Oncology Gulf Coast
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715753
Principal investigator 1 PFIZER INC. $26.00 12/08/2025 Non-covered Recipient Entity
Texas Oncology Gulf Coast
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715755
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Texas Oncology Gulf Coast
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715757
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Texas Oncology Gulf Coast
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715919
Principal investigator 1 PFIZER INC. $26.00 12/08/2025 Non-covered Recipient Entity
Texas Oncology Gulf Coast
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715921
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,725.00 10/31/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA
a randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer No dispute reported 06/30/2026 1185538827
Principal investigator 1 PFIZER INC. $957.00 10/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228727093
Principal investigator 1 PFIZER INC. $1,125.00 09/15/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228762180
Principal investigator 1 Eli Lilly and Company $0.24 07/24/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION No dispute reported 06/30/2026 1187892796
Principal investigator 1 Coherus Oncology, Inc. $23,500.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
CHS38802 No dispute reported 06/30/2026 1235252702
Principal investigator 1 PFIZER INC. $957.00 07/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228748735
Principal investigator 1 ABBVIE INC. $19,500.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (AndroMETa-CRC) No dispute reported 06/30/2026 1202495847
Principal investigator 1 PFIZER INC. $1,125.00 05/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228763815
Principal investigator 1 Eli Lilly and Company $26,799.00 04/15/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
CYCLONE 3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ABEMACICLIB IN COMBINATION WITH ABIRATERONE PLUS PREDNISONE IN MEN WITH HIGH-RISK METASTATIC HORMONE-SENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1187892004
Principal investigator 1 PFIZER INC. $957.00 04/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228750999
Principal investigator 1 Eli Lilly and Company $30,804.00 01/21/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION No dispute reported 06/30/2026 1187892742
Principal investigator 1 Eli Lilly and Company $4,248.00 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
CYCLONE 3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ABEMACICLIB IN COMBINATION WITH ABIRATERONE PLUS PREDNISONE IN MEN WITH HIGH-RISK METASTATIC HORMONE-SENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1187890548
Principal investigator 1 Eli Lilly and Company $45,328.68 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION No dispute reported 06/30/2026 1187892704
Principal investigator 1 PFIZER INC. $957.00 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228751003